Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Davanat filed for E.U. orphan drug status, advancing in phase II trials

March 2, 2007

Fenretinide receives orphan drug designations in U.S. and E.U.

March 2, 2007

Alpharadin improves survival in hormone-refractory prostate cancer

March 2, 2007

Addition of oblimersen to docetaxel may not be beneficial in advanced prostate cancer

March 2, 2007

AT-101 monotherapy induces responses in hormone-refractory prostate cancer

March 2, 2007

New therapeutic agents for cancer covered in recent patents

March 2, 2007

Cellular and molecular targets in tumor microenvironment considered for chemoprevention

March 1, 2007

Abiraterone active in androgen-independent, castration refractory prostate cancers

March 1, 2007

DMXAA increases efficacy of docetaxel in hormone-refractory prostate cancer

March 1, 2007

Paclitaxel poliglumex active, well tolerated in androgen-independent prostate cancer

March 1, 2007

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...